BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis.
Dedicated team
Contact information
2300 Englert Dr.
Durham, NC 27713
United States
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle Park, Cambridge, Massachussetts and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development of biologics across a wide range of disease states. BioAgilytix offers assay development, validation, and sample analysis under non‐GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc).
BioAgilytix is a bioanalytical partner to many of the top global pharmaceutical and biotechnology companies. The company also actively supports innovators that are working to progress large molecule breakthroughs, as well as smaller biotechs and emerging biopharma sponsors. Customers continue to choose BioAgilytix as their preferred bioanalytical CRO because of the company’s deep large molecule experience, reputation for quality, unparalleled regulatory track record and their uniquely collaborative approach.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. BioAgilytix’s scientific team’s collective experience supporting novel drug development for a wide range of disease areas has made the company a preferred partner for sponsors looking to create more effective biologic therapeutics in these fields. The company’s BPM (bioanalytical project manager) team averages 15+ years of post-school bench experience, with more than 35% comprised of PhD and Masters-level scientists that have been working with leading pharmaceutical and CROs for 10+ years. BioAgilytix’s scientists have supported the development of many key drugs currently on the market, as well as an array of promising clinical candidates, and understand the nuances in scientific, regulatory, and data requirements across disease states – as well as the challenges to anticipate in each phase.
Related news
Europe
United States
